The DOI matches its Crossref record; 92 of the 93 references it cites were found in a registry or an index.
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy
Abstract
In the last decade the serotonin transporter gene promoter polymorphism (5-HTTLPR) was likely the most studied genetic variant as predictor of antidepressant response. Nevertheless results are not consistent across studies and previous meta-analysis, since various factors seem to modulate its effect on antidepressant response. With the aim of clarifying this issue, we systematically reviewed literature, selecting 33 studies for an exploratory analysis without any a priori hypothesis. Then we analyzed separately 19 studies performed on Caucasians and 11 on Asians. We tested two phenotypes--remission and response rates--and three genotype comparisons--ll versus ls/ss, ss versus ll/ls and ll versus ss - using the Cochrane review manager. Evaluations were performed separately for SSRIs and mixed/other drugs. Possible clinical modulators were investigated. In the exploratory analysis, we found an association between l allele and l/l genotype and remission. When the analysis was split for ethnic group, in Caucasians we found an association between l allele and both response (OR = 1.58, C.I. 1.16-2.16, p = 0.004), and remission (OR = 1.53, C.I. 1.14-2.04, p = 0.004) in the SSRI group. Only a marginal association between l allele and remission (OR = 1.41, C.I. 1.02-1.95, p = 0.04) survived pooling together mixed antidepressant treatments. In Asians, a small effect of 5-HTTLPR on remission for mixed antidepressants was detected (OR = 2.10, C.I. 1.15-3.84, p = 0.02). Gender, age and age at onset modulated the association in Caucasians. Gender, age and depression severity at baseline modulated the association in Asians. In conclusion, in Caucasians 5-HTTLPR may be a predictor of antidepressant response and remission, while in Asians it does not appear to play a major role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pharmacogenetics studies have shown an association between certain polymorphisms in SLC6A4 and the response to antidepressants in patients with mood disorders.”
From Epigenetic mechanisms of major depression: Targeting neuronal plasticity (2018) · cites this paper as [131]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
(2014) · Medical Entomology and Zoology · Cited by 17,633
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Meta-analysis: Principles and procedures
Egger, M., Smith, G. D., & Phillips, A. N. (1997) · BMJ · doi:10.1136/bmj.315.7121.1533 · Cited by 2,415
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Hu, X.-Z., Lipsky, R., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B., Xu, K., Arnold, P., Richter, M., Kennedy, J., et al. (2006) · American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,215
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 728
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000698 · Cited by 636
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Pérez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
Self-citation
Cited by
Sorted by citations
Items 101–200 of 331
Plesničar, B. K., Terzić, T., Kastelic, M., & Dolžan, V. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s76494 · Cited by 27
GENETIC MODERATORS OF THE IMPACT OF PHYSICAL ACTIVITY ON DEPRESSIVE SYMPTOMS
Dotson, V. M., Hsu, F. C., Langaee, T. Y., McDonough, C. W., King, A. C., Cohen, R. A., Newman, A. B., Kritchevsky, S. B., Myers, V., Manini, T. M., et al. (2016) · The Journal of Frailty & Aging · doi:10.14283/jfa.2016.76 · Cited by 27
Crawford, A. A., Lewis, G., Lewis, S. J., & Munafo, M. R. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.12.001 · Cited by 26
Rotberg, B., Kronenberg, S., Carmel, M., Frisch, A., Brent, D. A., Zalsman, G., Apter, A., & Weizman, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0020 · Cited by 25
Miller, M. W., Sperbeck, E., Robinson, M. E., Sadeh, N., Wolf, E. J., Hayes, J. P., Logue, M. W., Schichman, S. A., Stone, A., Milberg, W., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00299 · Cited by 25
Dada, R., Tolahunase, M., & Sagar, R. (2018) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_398_17 · Cited by 26
The Limitations of Genetic Testing in Psychiatry
Dubovsky, S. L. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000443512 · Cited by 24
Ellerbrock, I., Sandström, A., Tour, J., Fanton, S., Kadetoff, D., Schalling, M., Jensen, K. B., Sitnikov, R., & Kosek, E. (2021) · Molecular Brain · doi:10.1186/s13041-021-00789-4 · Cited by 25
Pharmacogenetic‐based management of depression: Role of traditional Persian medicine
Jalali, A., Firouzabadi, N., & Zarshenas, M. M. (2021) · Phytotherapy Research · doi:10.1002/ptr.7134 · Cited by 22
The Potential Utility of Pharmacogenetic Testing in Psychiatry
Gardner, K. R., Brennan, F. X., Scott, R., & Lombard, J. (2014) · Psychiatry Journal · doi:10.1155/2014/730956 · Cited by 23
Predictors of Response and Remission to Antidepressants in Geriatric Depression: A Systematic Review
Masse, C., Bennabi, D., Giustiniani, J., Haffen, É., Vandel, P., & Chopard, G. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718807099 · Cited by 29
Matsumoto, Y., Fabbri, C., Pellegrini, S., Porcelli, S., Politi, P., Bellino, S., Iofrida, C., Mariotti, V., Melissari, E., Menchetti, M., et al. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0110-7 · Cited by 23
Self-citationShiroma, P. R., Drews, M. S., Geske, J. R., & Mrazek, D. A. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.02.012 · Cited by 24
Escitalopram Efficacy in Depression
Bousman, C., Sarris, J. J., Won, E., Chang, H.-S., Singh, A., Lee, H.-Y., Ham, B., Tan, C., Lee, M.-S., & Ng, C. H. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000165 · Cited by 23
Maciukiewicz, M., Marshe, V. S., Tiwari, A. K., Fonseka, T. M., Freeman, N., Rotzinger, S., Foster, J. A., Kennedy, J. L., Kennedy, S. H., & Müller, D. J. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.136 · Cited by 24
Hooten, W. M., Townsend, C. O., & Sletten, C. D. (2017) · Journal of Pain Research · doi:10.2147/jpr.s134231 · Cited by 23
A biocultural approach to psychiatric illnesses
Shattuck, E. C. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5178-7 · Cited by 24
Pharmacogenomics: an Update for Child and Adolescent Psychiatry
Namerow, L. B., Walker, S. A., Loftus, M., Bishop, J. R., Ruaño, G., & Malik, S. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01145-4 · Cited by 23
Kitzlerová, E., Fišar, Z., Lelková, P., Jirák, R., Zvěřová, M., Hroudová, J., Manukyan, A., Martásek, P., & Raboch, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907202 · Cited by 21
Arranz, M. J., Salazar, J., Bote, V., Artigas-Baleri, A., Serra-Llovich, A., Triviño, E., Roigé, J., Lombardía, C., Cancino, M., Hernández, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050999 · Cited by 21
Seripa, D., Pilotto, A., Paroni, G., Fontana, A., D’Onofrio, G., Gravina, C., Urbano, M., Cascavilla, L., Paris, F., Panza, F., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578159 · Cited by 23
Rothschild, A. J., Parikh, S. V., Hain, D., Law, R., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Shelton, R. C., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2020.113649 · Cited by 20
Pharmacogenomics and Biomarkers of Depression
Jha, M. K., & Trivedi, M. H. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_171 · Cited by 21
Genetic Prediction of Antidepressant Drug Response and Nonresponse in Korean Patients
Lim, S., Won, H., Kim, H. R., Myung, W., Kim, S., Kim, K.-K., Carroll, B. J., Kim, J., & Kim, D. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107098 · Cited by 20
Vilches, S., Tuson, M., Vieta, E., Álvarez, E., & Espadaler, J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090453 · Cited by 21
Wiggins, J. L., & Monk, C. S. (2013) · Development and Psychopathology · doi:10.1017/s095457941300062x · Cited by 21
The increasing challenge of the possible impact of ethnicity on psychopharmacology
Marazziti, D., Mucci, F., Avella, M. T., Palagini, L., Simoncini, M., & Dell’Osso, L. (2020) · CNS Spectrums · doi:10.1017/s1092852920000073 · Cited by 19
Sahraian, S., Babashams, M., Rezasoltani, P., Najmabadi, H., Kahrizi, K., & Gorgani, S. H. (2013) · Europe PMC (PubMed Central) · Cited by 19
Veldić, M., Ahmed, A. T., Blacker, C. J., Geske, J. R., Biernacka, J. M., Borreggine, K. L., Moore, K. M., Prieto, M. L., Voort, J. L. V., Croarkin, P. E., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00083 · Cited by 19
Personalized medicine in Alzheimer's disease and depression
Souslova, T., Marple, T. C., Spiekerman, A. M., & Mohammad, A. A. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.06.012 · Cited by 19
Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs
Eap, C. B. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.3/ceap · Cited by 22
Arakawa, R., Tateno, A., Kim, W., Sakayori, T., Ogawa, K., & Okubo, Y. (2016) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2016.03.006 · Cited by 16
The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes
Benitez, J., Jablonski, M., Allen, J. D., & Winner, J. G. (2015) · Applied & Translational Genomics · doi:10.1016/j.atg.2015.03.001 · Cited by 18
Lett, T. A. P., Walter, H., & Brandl, E. J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0385-9 · Cited by 19
THE SEROTONIN TRANSPORTER GENE AND DEPRESSION
Munafo, M. R. (2012) · Depression and Anxiety · doi:10.1002/da.22009 · Cited by 18
Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man
O’Leary, O. F., O'Brien, F. E., O’Connor, R. M., & Cryan, J. F. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.015 · Cited by 21
The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression
Dubovsky, S. L. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.998996 · Cited by 18
Bishop, J. R. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00006-3 · Cited by 18
Zięba, A., Matosiuk, D., & Kaczor, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032946 · Cited by 20
Ethnopsychopharmacology and Pharmacogenomics
Hernán Silva, I. (2013) · Advances in psychosomatic medicine · doi:10.1159/000348741 · Cited by 17
Mainstreaming Sex and Gender Analysis in Public Health Genomics
Verdonk, P., & Klinge, I. I. (2012) · Gender Medicine · doi:10.1016/j.genm.2012.10.006 · Cited by 17
Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants
Kang, H., Kim, K., Yoo, K.-H., Park, Y., Kim, J., Kim, J., Shin, I.-S., Kim, J. H., & Kim, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144884 · Cited by 17
Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients
Dong, B., Zou, C., Flaherty, J. H., & Ding, X. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s38899 · Cited by 18
Poland, R. E., Lesser, I. M., Wan, Y. Y., Gertsik, L., Yao, J., Raffel, L. J., Lin, K.-M., & Myers, H. F. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.03.009 · Cited by 17
Yamazaki, K., Yoshino, Y., Mori, T., Okita, M., Yoshida, T., Mori, Y., Ozaki, Y., Sao, T., Iga, J., & Ueno, S. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000447324 · Cited by 16
Translational Functional Neuroimaging in the Explanation of Depression
Stoyanov, D., Kandilarova, S., & Borgwardt, S. (2017) · Balkan Medical Journal · doi:10.4274/balkanmedj.2017.1160 · Cited by 16
Fuying, Z., Yingying, Y., Shining, Z., Kezhong, Z., Shi, Y., Xuemei, Z., Yin, C., Jinxia, C., Li, H., Wu, Y., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.023 · Cited by 16
Howard, P. D., Twycross, R., Shuster, J. L., Mihalyo, M., & Wilcock, A. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.09.001 · Cited by 21
Chang, D. D., Eyre, H. A., Abbott, R. B., Coudreaut, M. F., Baune, B. T., Shaman, J. A., Lavretsky, H., Lenze, E. J., Merrill, D. A., Singh, A., et al. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0099 · Cited by 16
What is the role of pharmacogenetics in clinical psychiatry?
Lombard, J., & Doraiswamy, P. M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.733696 · Cited by 16
Schiele, M. A., Reif, A., Lin, J., Alpers, G. W., Andersson, E., Andersson, G., Arolt, V., Bergström, J., Carlbring, P., Eley, T. C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.004 · Cited by 15
Zou, Z., Huang, Y., Wang, J., Min, W., & Zhou, B. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02790-y · Cited by 15
Joharchi, K., Memari, M., Azargashb, E., & Saadat, N. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00427-w · Cited by 15
Janet, R., Costes, N., Mérida, I., Derrington, E. A., & Dreher, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-28667-0 · Cited by 15
Understanding the pharmacogenetics of selective serotonin reuptake inhibitors
Fabbri, C., Minarini, A., Niitsu, T., & Serretti, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.928693 · Cited by 14
Self-citationAvinun, R., Nevo, A., Radtke, S. R., Brigidi, B. D., & Hariri, A. R. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01040-x · Cited by 15
Sforzini, L. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100331 · Cited by 14
Popa, N., Bachar, D., Roberts, A., Santangelo, A. M., & Gascon, E. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104159 · Cited by 13
Strawn, J. R., Poweleit, E. A., Mills, J. A., Schroeder, H. K., Neptune, Z. A., Specht, A. M., Farrow, J. E., Zhang, X., Martin, L. J., & Ramsey, L. B. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111188 · Cited by 15
Yoshida, K., Koyama, E., Zai, C. C. H., Beitchman, J. H., Kennedy, J. L., Lunsky, Y., Desarkar, P., & Müller, D. J. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720971950 · Cited by 13
Manzanares, J., Sala, F., García‐Gutiérrez, M. S., & Rueda, F. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00060-8 · Cited by 12
Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients
Mas, S., Blázquez, A., Rodríguez, N., Boloc, D., Lafuente, A., Arnáiz, J. A., Lázaro, L., & Gassó, P. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000240 · Cited by 12
Pharmacogenetic studies: a tool to improve antidepressant therapy
Ramos, M., Berrogain, C., Concha, J., Lomba, L., García, C. B., & Ribate, M. P. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0019 · Cited by 12
Leveraging genetics to enhance the efficacy of PTSD pharmacotherapies
Miller, M. W. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.039 · Cited by 13
Calabrò, M., Mandelli, L., Crisafulli, C., Porcelli, S., Albani, D., Politis, A. M., Papadimitriou, G. N., Nicola, M. D., Janiri, L., Colombo, R., et al. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05119-5 · Cited by 10
Self-citationRamesh, V., Venkatesan, V., & Ramasamy, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2830 · Cited by 14
Camarena, B., Álvarez-Icaza, D., Hernández, S., Aguilar, A., Münch-Anguiano, L., Martínez, C., & Becerra‐Palars, C. (2018) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000315 · Cited by 11
Clinical utility of pharmacogenetics-guided treatment of depression and anxiety
Boland, J. R., Duffy, B. C., & Myer, N. M. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.11.001 · Cited by 13
Tanahashi, S., Tanii, H., Konishi, Y., Otowa, T., Sasaki, T., Tochigi, M., Okazaki, Y., Kaiya, H., & Okada, M. (2020) · Neuropsychobiology · doi:10.1159/000512699 · Cited by 14
Towbin, K. E., Solages, M. M., & Stubbe, D. E. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch12 · Cited by 12
Mandal, T., Bairy, L. K., & Sharma, P. S. V. N. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02866-4 · Cited by 14
Henry, M., Lauriat, T. L., Lowen, S. B., Churchill, J. H., Hodgkinson, C. A., Goldman, D. A., & Renshaw, P. F. (2013) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2013.05.008 · Cited by 10
SLC6A45HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome
Šenk, B., Goričar, K., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2018) · International Journal of Endocrinology · doi:10.1155/2018/6130487 · Cited by 10
The Pharmacogenomics of Selective Serotonin Reuptake Inhibitors
García‐Marín, L. M., Rabinowitz, J. A., Ceja, Z., Alcauter, S., Medina-Rivera, A., & Rentería, M. E. (2022) · Pharmacogenomics · doi:10.2217/pgs-2022-0037 · Cited by 11
Pharmacogenetic studies of drug response in schizophrenia
Arranz, M. J., Gallego-Fábrega, C., Salazar, J., & Arias, B. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1140554 · Cited by 10
Stevenson, J. M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0196 · Cited by 10
Jaros, A., Rybakowski, F., Cielecka‐Piontek, J., Paczkowska‐Walendowska, M., Czerny, B., Kamiński, A., Elsorady, R. W. M., & Bienert, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111397 · Cited by 11
Ivanov, R. A., Zamyatin, V., Klimenko, A. I., Matushkin, Y. G., Savostyanov, A. N., & Lashin, S. A. (2019) · Genes · doi:10.3390/genes10090699 · Cited by 9
Organic cation transporters in psychiatric and substance use disorders
Honan, L. E., Fraser‐Spears, R., & Daws, L. C. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108574 · Cited by 9
Kim, Y.-G., Chang, H. S., Won, E., Ham, B., & Lee, M.-S. (2014) · Neuropsychobiology · doi:10.1159/000362241 · Cited by 9
Gressier, F., Verstuyft, C., Hardy, P., Becquemont, L., & Corruble, E. (2014) · Archives of Women s Mental Health · doi:10.1007/s00737-014-0464-1 · Cited by 9
Bang, M., Kim, B., Lee, K. S., Choi, T. K., & Lee, S.-H. (2021) · Mindfulness · doi:10.1007/s12671-021-01667-9 · Cited by 9
Singh, A. B., Bousman, C., Ng, C. H., Byron, K. A., & Berk, M. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.53 · Cited by 9
Watanabe, S., Iga, J., Numata, S., Umehara, H., Nishi, A., Kinoshita, M., Inoshita, M., & Ohmori, T. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.009 · Cited by 8
Takahashi, H., Yoshida, K., Higuchi, H., Kamata, M., Inoue, K., Suzuki, T., & Ishigooka, J. (2014) · Neuropsychobiology · doi:10.1159/000365517 · Cited by 7
Interactive effect of 5-HTTLPR genotype and age on sources of cortical rhythms in healthy women
Volf, N. V., Belousova, L. V., Knyazev, G. G., & Kulikov, V. A. (2016) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2016.09.002 · Cited by 8
Du, D., Tang, Q., Han, Q., Zhang, J., Liang, X., Tan, Y., Liu, K., & Xiang, B. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0037 · Cited by 8
Hongkaew, Y., Gaedigk, A., Wilffert, B., Gaedigk, R., Kittitharaphan, W., Ngamsamut, N., Limsila, P., Puangpetch, A., Sukprasong, R., & Sukasem, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743494 · Cited by 10
Calabrò, M., Fabbri, C., Crisafulli, C., Albani, D., Forloni, G., Kasper, S. F., Sidoti, A., Velardi, E., Zohar, J., Juven‐Wetzler, A., et al. (2018) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2682 · Cited by 8
Self-citationBeaver, J. N., Weber, B. L., Ford, M. T., Anello, A. E., Kassis, S. K., & Gilman, T. L. (2022) · Cells · doi:10.3390/cells11121874 · Cited by 7
Genotyping of patients treated with selective serotonin reuptake inhibitors
Solhaug, V., Haslemo, T., Kringen, M. K., Molden, E., & Dietrichs, E. S. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0017 · Cited by 7
Pettitt, A. (2015) · eNeuro · doi:10.1523/eneuro.0032-14.2015 · Cited by 7
Towards personalized treatment of depression: A candidate gene approach
Landrø, N. I. (2014) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12124 · Cited by 7
Nguyen, T. B., Gunn, J. M., Potiriadis, M., Everall, I., & Bousman, C. (2015) · BJPsych Open · doi:10.1192/bjpo.bp.115.000380 · Cited by 7
Pharmakogenetik in der Psychiatrie: eine Standortbestimmung
Genetik, D. D. R. N. U., Müller, D., Brandl, E. J., Degenhardt, F., Domschke, K., Grabe, H. J., Gruber, O., Hebebrand, J., Maier, W., Menke, A., et al. (2018) · Der Nervenarzt · doi:10.1007/s00115-017-0479-8 · Cited by 8
Review of Pharmacogenomics of Psychiatric Comorbidities in Autism Spectrum Disorder
Pedrero, A. Á., Bote, V., Lamborena, C., Medina, R., Serra-Llovich, A., Amaia Hervas, G., & Arranz, M. J. (2023) · Pharmacogenomics · doi:10.2217/pgs-2023-0134 · Cited by 6
Ivanets, N. N., Kinkulkina, M. A., Tikhonova, Y. G., Avdeeva, T. I., Ragimov, A. A., Дашкова, Н. Г., Kuznetsov, O. E., Matveev, A. V., Izyumina, T. A., & Orlov, S. V. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20161162146-51 · Cited by 6
Deniz, S., Sancar, M., Okuyan, B., Ata, P., Özakpınar, Ö. B., Talas, A., Güneş, T., Çalışkan, M., & İzzettin, F. V. (2016) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20151003060610 · Cited by 6
Personalized TMS: role of RNA genotyping
Chan, S. T., & Bota, R. G. (2019) · Mental Illness · doi:10.1108/mij-10-2019-0004 · Cited by 6
Kesić, M., Mokrović, G., Tvrdeić, A., Miše, B., Štefulj, J., & Čičin‐Šain, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.741222 · Cited by 6
Metadata
- Authors
- Porcelli, S., Fabbri, C., & Serretti, A.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Serretti, Alessandro
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 22
- Issue
- 4
- Pages
- 239-258
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2035090322
- Cited by
- 331
- References
- 93
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 8 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 19 · 2019: 20 · 2018: 31 · 2017: 27 · 2016: 42 · 2015: 33 · 2014: 27 · 2013: 36 · 2012: 13
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- 5-HTTLPR, serotonin transporter gene, promoter polymorphism, antidepressant response, antidepressant remission, genetic predictors of treatment response, selective serotonin reuptake inhibitors, ethnic differences, Caucasians, Asians, age of onset, depression severity, sex differences
- MeSH terms
- Age Factors, Alleles, Antidepressive Agents, Depression, Female, Genotype, Humans, Male, Polymorphism, Genetic, Promoter Regions, Genetic, Remission Induction, Sex Factors, White People, Asian People, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review